Related Experiment Video

Updated: Aug 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC

Tong Zhou1, Huan Yi2, Chan Zhu2

  • 1Medical Oncology Department, The Fourth People's Hospital of Changzhou, Changzhou, China.

Investigational New Drugs
|April 10, 2023
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Experiment Videos

Last Updated: Aug 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

Bridging physics and biology in acupuncture: flexible multimodal bioelectronics for decoding the deqi microenvironment.

Frontiers in bioengineering and biotechnology·2026

Chitosan-based nerve guidance conduits functionalized with fibroblast-derived extracellular vesicles promote peripheral nerve regeneration via miR-143-3p delivery.

Bioactive materials·2026

Plasma proteomics-based liquid biopsy for predicting efficacy of PD-1-based immunochemotherapy in advanced gastric cancer: a prospective cohort study.

Molecular biomedicine·2026

Association between D-dimer difference and risk of postoperative venous thromboembolism in endometrial cancer: a retrospective cohort study.

Thrombosis journal·2026

Long-Term Outcomes After Cervical Cold Knife Conization or Loop Electrosurgical Excision Procedure.

JAMA surgery·2026

Efficacy and safety of immunotherapy in head and neck tumors: a systematic review and meta-analysis of clinical outcomes and survival benefits.

Frontiers in oncology·2026

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.

Investigational new drugs·2026

The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells.

Investigational new drugs·2026

Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.

Investigational new drugs·2026

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Investigational new drugs·2026

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026

Lathyrol Targets G6PD to Disrupt Redox Homeostasis in Non-Small Cell Lung Cancer.

ACS omega·2026

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

JTO clinical and research reports·2026

Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice.

JTO clinical and research reports·2026

Use of the Behavioral Dyscontrol Scale-2 (BDS-2) to measure executive dysfunction in FXTAS.

Frontiers in molecular neuroscience·2026

Targeted niosomes protect the heart from doxorubicin-induced injury: evidence from oxidative stress, pyroptosis, and apoptosis pathways.

3 Biotech·2026

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us